To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis

NCT02528760 | Completed

• 1 other identifier: ILBS-Cirrhosis-005
• Study Type: interventional
• Target: 83
• Locations: 1 country
• Sites: 1

Brief Summary

1. 1.All patients with chronic liver disease admitted in ICU (Intensive Care Unit) to be screened.
2. 2.Patients fulfilling criteria for feed intolerance to be included in the study.
3. 3.Patients to undergo routine biochemical and hematological testing including CBC, KFT, LFT, PT/INR, electrolytes baseline and daily along with ABG (Arterial Blood gas) analysis.
4. 4.Patients with ascites to be tested for presence or absence of SBP (Spontaneous Bacterial Peritonitis).
5. 5.Cultures to be sent as based on clinical parameter of the patient.
6. 6.All correctable causes for intra abdominal hypertension to be corrected including electrolyte imbalance, grade III ascites, intra abdominal infection.
7. 7.Symptoms- Absent bowel sounds (BS)= no BS detected by auscultation. Vomiting/regurgitation= any visible regurgitation of gastric contents; Diarrhoea= liquid stool \> or =3 times/day; Bowel distension= suspected clinically and radiologically confirmed; Large gastric residual volume (GRV) of \>or =500 ml/24 h on a single day or \> 200ml at any time of the day.
8. 8.Per abdomen findings to be checked daily including presence of bowel sounds, tenderness, development of abdominal distension, abdominal girth monitoring and abdominal pressure monitoring.
9. 9.Patients who develop feed intolerance will be included.
10. 10.Feed intolerance to be defined as per study definition (3 out of 5 symptoms).
11. 11.Measurement of GRV (Gastric residual volume) to be done at 4 hourly interval.
12. 12.Methods for measuring GRV by either gravity drainage by connecting a gastric tube to a drainage bag for 10min or by manual aspiration of content using a 50ml syringe.
13. 13.Once feed intolerance develop than every 6 hourly intra abdominal pressure monitoring and abdominal girth monitoring to be done (24)
14. 14.Intra bladder pressure to be measured using Foleys manometer technique (25).
15. 15.Pressure measured in cm of water to be converted into mm of Hg.
16. 16.X ray abdomen supine to look for bowel distension, defined as more than 3 cm for small bowel and more than 5 cm in large bowel.
17. 17.Development of intra abdominal hypertension based on intra abdominal pressure.
18. 18.Patient to be stratified according to the grade of intra-abdominal hypertension.
19. 19.After correction of all correctable causes, if feed intolerance persists, then patient to be randomized by block randomization method into 3 arms, metaclopromide group, erythromycin group or placebo group.
20. 20.Daily assessment of bowel sounds, abdominal pressure, abdominal girth every 6 hourly and gastric residual volume to be noted every 4 hourly.
21. 21.Response of therapy to be assessed at 24 hours in each arm.
22. 22.Response to be assessed by resolution of feed intolerance or initiation of entral nutrition.
23. 23.Metoclopromide to be given 10mg iv 8 hourly.
24. 24.Erythromycin to be given 70mg iv 12 hourly (26).
25. 25.Placebo arm to receive normal saline in 10ml syring twice daily.
26. 26.After 24 hours of treatment if symptoms do not resolve than rescue treatment will be given to each arm which may include continuation of prokinetics, add on prokinetic, flatus tube insertion for bowel decompression, upgradation of antibiotics or search for any other cause, as per the patient response.
27. 27.Therapy to continue for a total duration of 72 hours.
28. 28.If there is no response at 72 hours, than study stops.
29. 29.If patient responds to given treatment, study to continue for a total duration of 7 days.
30. 30.Assessment to continue in each arm for a maximum period of 7 days.

Conditions

Cirrhosis

Outcome Measures

Primary Outcomes (1)

• Resolution of feed intolerance at 24 hours with improvement in 3 or more points and initiation of entral feeding.

  Feed intolerance to be defined as 3/5 symptoms which include gastric residual volume \> 500 ml /day,absence of bowel sounds,vomitting/regurgitation,diarrhoea and bowel distension

  24 hours

Secondary Outcomes (7)

• Survival

  72 hours

• Survival

  7 days

• Number of patients with Initiation of entral nutrition more than 50%. of recommended nutrition (Kcal/kg body weight/day).

  72 hours

• Number of patients with resolution of atleast 2 out of 5 symptoms in all the 3 groups.

  72 hours

• Number of patients with resolution of sepsis, shock, organ failure in all the 3 groups.

  7 days

Study Arms (3)

Metaclopromide group

EXPERIMENTAL

Drug: Metaclopramide

Erythromycin group

EXPERIMENTAL

Drug: Erythromycin

Placebo group

PLACEBO COMPARATOR

Other: Placebo

Interventions

Metaclopramide DRUG

23\. Metoclopromide to be given 10mg iv 8 hourly

Metaclopromide group

Erythromycin DRUG

Erythromycin to be given 70mg iv 12 hourly.

Erythromycin group

Placebo OTHER

Placebo group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Patients who develop new onset feed intolerance to enteral nutrition

You may not qualify if:

• Any patient with current or past surgical abdomen including mechanical obstruction, mesenteric ischemia, perforation or requiring abdominal surgery.
• Patients receiving enteral nutrition through gastrostomy or jejunostomy.
• Patients in whom, prokinetics are contraindicated or are allergic to the same.
• Patients who received prokinetic more than one day prior to the start of enteral feeding.
• Patients with uncontrolled sepsis with DIC.
• Requirement of two or more vasopressors.
• Organ failure requiring high inotropic support.
• Advanced cardiopulmonary disease, with prior history of arrhythmias, structural heart disease.
• History of traumatic brain injury, raised intracranial pressure, history of myasthenia gravis.
• Endocronolgic illnesses: Hypothyroidism, hypoparathyroidism
• Connective tissue diseases (systemic sclerosis, dermatomyositis or polymyositis, systemic lupus erythematosis, amyloidosis).
• Known case of diabetes with diabetic gastroparesis
• Pregnancy
• Patients or concerned family member who fail to give consent for study enrollment
• Age less than 18 years and more than 70 years.

Sponsors & Collaborators

• Institute of Liver and Biliary Sciences, India: lead

Study Sites (1)

Institute of liver and Biliary Sciences

New Delhi, National Capital Territory of Delhi, 110070, India

Location

MeSH Terms

Conditions

Fibrosis

Interventions

Metoclopramide; Erythromycin

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Benzamides; Amides; Organic Chemicals; para-Aminobenzoates; Aminobenzoates; Benzoates; Acids, Carbocyclic; Carboxylic Acids; Chlorobenzoates; Hydroxybenzoate Ethers; Hydroxybenzoates; Hydroxy Acids; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Phenyl Ethers; Phenols; Macrolides; Polyketides; Lactones

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 17, 2015
• First Posted: August 19, 2015
• Study Start: September 24, 2015
• Primary Completion: August 31, 2017
• Study Completion: August 31, 2017
• Last Updated: November 21, 2017

Record last verified: 2016-09

Locations

IN (1)